Switching From Usual Brand Cigarettes to a Tobacco-heating Cigarette or Snus

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

163 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-02-28

Study Completion Date

2009-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate selected biomarkers of tobacco exposure and biomarkers of harm and assess quality of life measures in smokers randomly switched from their usual brand of cigarette to one of three test products: (1) a tobacco-heating cigarette; (2) snus (smokeless tobacco); or (3) an ultra-low machine yield tobacco-burning cigarette.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Changes in Biomarker of Exposure in Adults Who Smoke Cigarettes Switching From Cigarettes to Heated Tobacco Products

NCT06179290

Tobacco Use

COMPLETED NA

BAT3221032: A Study to Evaluate the Effects of Switching From Cigarette Smoking to Using One of Five Variants of a Heated Tobacco Product on Biomarkers of Exposure and Biomarkers of Potential Harm in Healthy Subjects

NCT05142436

Smoking Tobacco Use Tobacco Smoking

COMPLETED NA

Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors

NCT02000921

Tobacco Addiction Dual Tobacco Use

COMPLETED NA

Development of Biomarkers of Effect From Chronic Tobacco Usage

NCT01923402

Cigarette Smoking

COMPLETED

Post-Market Surveillance of Tobacco Products

NCT04255459

Smoking, Tobacco Smoking Behaviors

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A randomized, multi-center, 4-group study of health status measures and biomarkers in subjects who smoke and are switched to either a tobacco-heating cigarette, snus, or a tobacco-burning cigarette, with a non-treatment group of never-smokers.

Primary Objectives:

* Evaluate select biomarkers of tobacco exposure and biomarkers of harm from subjects who smoke and who are switched to a tobacco-heating cigarette, snus, or a tobacco-burning cigarette.
* Evaluate ability of a tobacco-heating cigarette and snus to modify patient-reported Chronic Obstructive Pulmonary Disease (COPD)-related health status in subjects who smoke and are switched to either a tobacco-heating cigarette or snus relative to a control group (a tobacco-burning ultra-low machine yield \[ULMY\]) cigarette.
* Assess subject compliance.

Secondary Objectives:

* Measure amount and repeatability of smoke components yielded from the cigarettes (yield in use) and determine relative uptake of selected smoke components.
* Evaluate the ability of a tobacco-heating cigarette and snus to modify general health status as measured by self-administered health questionnaires in subjects who smoke and are switched to either a tobacco-heating cigarette or snus relative to a control group (a tobacco-burning ULMY cigarette).
* Compare health status measures in smokers who are switched to a tobacco-heating cigarette to smokers who are switched to snus.
* Compare baseline data from all tobacco-using groups to baseline data from the never-smoking (non-treatment) group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cigarette Smoking

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tobacco-Heating Cigarette

A group of 44 subjects who smoke and are switched to a tobacco-heating cigarette

Group Type EXPERIMENTAL

Tobacco-Heating Cigarette

Intervention Type OTHER

Smokers switched to a tobacco-heating cigarette for 24 weeks

Snus (Smokeless Tobacco)

A group of 43 subjects who smoke and are switched to snus (smokeless tobacco)

Group Type EXPERIMENTAL

Snus (Smokeless Tobacco)

Intervention Type OTHER

Smokers switched to snus product for 24 weeks

Tobacco-Burning Cigarette

A group of 44 subjects who smoke and are switched to a tobacco-burning ultra-low machine yield cigarette

Group Type EXPERIMENTAL

Tobacco-Burning Cigarette

Intervention Type OTHER

Smokers switched to a tobacco-burning cigarette for 24 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tobacco-Heating Cigarette

Smokers switched to a tobacco-heating cigarette for 24 weeks

Intervention Type OTHER

Snus (Smokeless Tobacco)

Smokers switched to snus product for 24 weeks

Intervention Type OTHER

Tobacco-Burning Cigarette

Smokers switched to a tobacco-burning cigarette for 24 weeks

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females, between 28 and 55 years of age, inclusive.
* Cigarette-only smokers who currently smoked at least 15 cigarettes daily and who smoked for at least 10 years prior to Week 0 (i.e., chronic cigarette smokers).
* Smokers not intending to quit smoking, but willing to switch their tobacco product (intent to quit was defined as intending to make or making a quit attempt within 1 month prior to Week 0).
* Non-smoking subjects who self-reported "Never-Smoker" per the American Thoracic Society Questionnaire definition, and did not have urinary cotinine levels exceeding 50 ng/mL.
* Subjects, in the opinion of the Investigators, free of clinically significant health problems and not on medication on a daily basis for chronic medical disorders deemed clinically significant by the Investigator(s).
* Subjects not regularly taking creatine supplements.
* Subjects testing negative for selected drugs of abuse at Screening (included alcohol test).
* Subjects with a negative hepatitis panel (including hepatitis B surface antigen \[HBsAg\] and hepatitis C virus antibody \[anti-HCV\]) and negative Human Immunodeficiency Virus (HIV) antibody screens (for subjects immunized against hepatitis B with documentation of this immunization, a positive test result was not exclusionary).
* Female subjects who were non-pregnant (urine pregnancy test results were negative at Screening and Weeks 0, 12, and 24), non-lactating, and either postmenopausal (as verified by Follicle Stimulating Hormone levels) for at least 1 year, surgically sterile (e.g., tubal ligation, hysterectomy) for at least 90 days, or agreed to use from the time of signing the informed consent until 30 days after Week 24 (or Study Completion) a form of contraception considered acceptable to the Investigators (such as oral, injectable or implantable contraceptives, intrauterine devices and barrier methods ).
* Subjects able to read and comprehend questionnaires in English and willing to sign an Informed Consent Form.

Exclusion Criteria

* Smokers using any other tobacco or nicotine-containing product or device other than tobacco-burning cigarettes from 6 months prior to the study through Week 24, including cigars, pipes, chewing tobacco, snuff, snus, nicotine patch, nicotine gum, etc.
* A history or clinical manifestations of significant metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological, or psychiatric disorders.
* A history of hypersensitivity or allergies to any drug compound unless approved by the Investigator(s).
* A history or presence of an abnormal ECG deemed clinically significant by the Investigator.
* A history of alcoholism or drug addiction within 1 year prior to Study Entry.
* Evidence of visible oral cancer, as found in an oral health examination or based on oral health questions at each visit.
* Any acute or chronic condition that, in the Investigator(s)' opinion, limited the subject's ability to complete and/or participate in the study.
* Donation of blood from 30 days prior to Screening through Week 24 (or Study Completion), inclusive, or plasma from 2 weeks prior to Screening through Week 24 (or Study Completion), inclusive.
* Receipt of blood products within 2 months prior to Study Entry.
* Subject or a relative of the subject was currently or had ever been employed by the tobacco industry.
* Subject participated in any other investigational study drug or product trial in which receipt of an investigational study drug or product occurred within 30 days prior to Check-in (inclusive).

Minimum Eligible Age

28 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes